Dna Methylation is an important component in the neurobiology of neurodegenerative [diseases](/diseases). This page provides detailed information about its structure, function, and role in disease processes.
Overview
DNA methylation is an epigenetic modification involving the addition of a methyl group to the 5-position of cytosine residues in DNA (forming 5-methylcytosine, 5mC). This reversible, heritable modification regulates gene expression without altering the underlying DNA sequence and plays crucial roles in brain development, neuronal identity, [synaptic plasticity](/mechanisms/synaptic-plasticity), and [aging](/diagnostics/neuroimaging). Aberrant DNA methylation patterns are increasingly recognized as a core feature of [Alzheimer's disease](/diseases/alzheimers-disease) and other neurodegenerative disorders, linking environmental exposures and aging to altered gene expression and neuronal vulnerability ([Coppieters et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25245166/); [Day & Bhatt, 2024](https://pmc.ncbi.nlm.nih.gov/articles/PMC11045197/)). [@portela2010]
DNA methylation is part of a broader epigenetic landscape that includes [histone modifications](/entities/histone-modifications), non-coding RNA regulation, and chromatin remodeling, all of which interact to determine gene expression states in the aging and diseased brain. [@globisch2010]
Molecular Mechanisms
DNA Methyltransferases (DNMTs)
...
DNA Methylation
Introduction
Dna Methylation is an important component in the neurobiology of neurodegenerative [diseases](/diseases). This page provides detailed information about its structure, function, and role in disease processes.
Overview
DNA methylation is an epigenetic modification involving the addition of a methyl group to the 5-position of cytosine residues in DNA (forming 5-methylcytosine, 5mC). This reversible, heritable modification regulates gene expression without altering the underlying DNA sequence and plays crucial roles in brain development, neuronal identity, [synaptic plasticity](/mechanisms/synaptic-plasticity), and [aging](/diagnostics/neuroimaging). Aberrant DNA methylation patterns are increasingly recognized as a core feature of [Alzheimer's disease](/diseases/alzheimers-disease) and other neurodegenerative disorders, linking environmental exposures and aging to altered gene expression and neuronal vulnerability ([Coppieters et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25245166/); [Day & Bhatt, 2024](https://pmc.ncbi.nlm.nih.gov/articles/PMC11045197/)). [@portela2010]
DNA methylation is part of a broader epigenetic landscape that includes [histone modifications](/entities/histone-modifications), non-coding RNA regulation, and chromatin remodeling, all of which interact to determine gene expression states in the aging and diseased brain. [@globisch2010]
Molecular Mechanisms
DNA Methyltransferases (DNMTs)
Three major DNMT enzymes catalyze methylation reactions ([Portela & Esteller, 2010](https://pubmed.ncbi.nlm.nih.gov/22293439/)): [@day2015]
| Enzyme | Type | Key Function | Brain Expression | [@day2024] |--------|------|-------------|-----------------| [@ref] | DNMT1 | Maintenance | Copies methylation patterns to daughter strands during DNA replication | High in post-mitotic [Neurons](/cell-types/neurons); maintains neuronal identity | [@horvath2013] | DNMT3A | De novo | Establishes new methylation marks | Active in adult [neurogenesis](/entities/neurogenesis) and synaptic plasticity | [@smart2018] | DNMT3B | De novo | Establishes methylation during embryonic development | Lower postnatal expression; variants linked to ICF syndrome | [@refa] | DNMT3L | Regulatory | Stimulates DNMT3A/B activity; lacks catalytic domain | Important in genomic imprinting | [@levine2018]
Methylation and Demethylation Cycle
DNA methylation is a dynamic, reversible process: [@npj2025]
Methylation: DNMTs transfer a methyl group from S-adenosylmethionine (SAM) to cytosine at CpG dinucleotides
Oxidation: TET (Ten-Eleven Translocation) enzymes oxidize 5mC to 5-hydroxymethylcytosine (5hmC), then to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC)
Demethylation: Thymine DNA glycosylase (TDG) excises 5fC and 5caC; base excision repair (BER) restores unmodified cytosine
5-hydroxymethylcytosine (5hmC) is particularly abundant in the brain — approximately 10-fold higher than other tissues — and is enriched at active gene bodies and enhancers, where it serves as a stable epigenetic mark rather than merely a transient intermediate ([Globisch et al., 2010](https://pubmed.ncbi.nlm.nih.gov/22353756/)). [@lord2014]
CpG Context and Gene Regulation
| Methylation Context | Effect on Expression | Brain Relevance | |-------------------|---------------------|-----------------| | CpG island promoters | Methylation → silencing | Controls expression of synaptic and neuronal identity [genes](/genes) | | Gene bodies | Methylation → active transcription | Regulates alternative splicing; enriched for 5hmC in [Neurons](/cell-types/neurons) | | Enhancers | Cell-type-specific methylation patterns | Determines [neurons](/entities/neurons) vs. glia] gene expression programs | | Non-CpG (CpH) methylation | Unique to [Neurons](/cell-types/neurons); brain-specific | Accumulates during postnatal brain maturation; may regulate neuronal gene expression | | Repetitive elements | Methylation maintains silencing | Loss of methylation at LINE-1 elements linked to [aging and neurodegeneration](/mechanisms/aging-neurodegeneration) |
The brain exhibits unique methylation characteristics not seen in other tissues:
High 5hmC levels: Brain has the highest 5hmC content of any organ, particularly in [Neurons](/cell-types/neurons) of the [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and [cerebellum](/brain-regions/cerebellum)
Non-CpG methylation: [Neurons](/cell-types/neurons) accumulate substantial CpH methylation (CpA, CpT, CpC) during postnatal development — a feature unique to brain cells
Cell-type specificity: Dramatic differences in methylation patterns between [Neurons](/cell-types/neurons), [Astrocytes](/cell-types/astrocytes), [microglia:
Global DNA hypomethylation in vulnerable regions ([hippocampus](/brain-regions/hippocampus), [entorhinal cortex](/brain-regions/entorhinal-cortex), [prefrontal [cortex)
Reduced 5hmC levels, particularly in hippocampal [Neurons](/cell-types/neurons)
Epigenome-wide association studies (EWAS) have identified hundreds of differentially methylated positions (DMPs) associated with AD neuropathology
Cell-type deconvolution reveals that many DMPs in bulk [cortex](/brain-regions/cortex) tissue reflect methylation changes in non-neuronal cells ([microglia](/cell-types/microglia)/cell-types/microglia:**
[BDNF](/proteins/bdnf): Reduced trophic support for hippocampal and cortical [Neurons](/cell-types/neurons)
ANK1: Consistently identified as hypermethylated in the [entorhinal cortex](/brain-regions/entorhinal-cortex); one of the most robust EWAS findings in AD
HOXA3, BIN1, RHBDF2: Genome-wide significant DMPs replicated across multiple cohorts
SYP, CREB: Synaptic plasticity genes with reduced expression
Hypomethylated genes (activated in AD):
**[BACE1](/entities/bace1) can slow epigenetic aging
DNA Methylation in Other Neurodegenerative Diseases
Parkinson's Disease
Altered methylation at the [SNCA](/genes/snca) locus: hypomethylation of SNCA intron 1 increases [alpha-synuclein](/proteins/alpha-synuclein) expression
[LRRK2](/genes/lrrk2) and [GBA](/genes/gba) methylation changes in PD blood and brain
Accelerated epigenetic aging in [substantia nigra](/brain-regions/substantia-nigra) dopaminergic [neurons](/entities/neurons)
ALS
[C9orf72](/genes/c9orf72) repeat expansion carriers show hypermethylation of the [C9orf72](/genes/c9orf72) promoter
Aberrant methylation of [SOD1](/proteins/sod1-protein) and [TARDBP](/genes/tardbp) loci
Epigenetic aging of motor [Neurons](/cell-types/neurons) in [ALS](/diseases/amyotrophic-lateral-sclerosis)
Huntington's Disease
Altered methylation patterns near the [HTT](/genes/htt) locus in [Huntington's disease](/diseases/huntingtons)
Accelerated epigenetic aging in striatal tissue correlates with CAG repeat length
Therapeutic Implications
Pharmacological Approaches
DNMT inhibitors:
5-azacytidine (Vidaza) and decitabine: FDA-approved for hematological malignancies; preclinical AD studies show mixed results
RG108: Non-nucleoside DNMT inhibitor with improved safety profile
Challenges: Lack of gene specificity; global demethylation may activate deleterious genes
TET enzyme modulators:
Vitamin C enhances TET enzyme activity and promotes 5hmC formation
Restoring 5hmC levels may be therapeutically beneficial in AD
[HDAC](/entities/hdac-enzymes) inhibitors]:
Interact with DNA methylation pathways; combined epigenetic therapy approaches under investigation
Precision Epigenetic Editing
CRISPR-dCas9-DNMT3A: Targeted methylation of specific genomic loci without altering DNA sequence
CRISPR-dCas9-TET1: Targeted demethylation for reactivating silenced genes
Proof-of-concept in neuronal cultures; delivery challenges for CNS applications
Lifestyle and Dietary Interventions
Modifiable factors that influence brain DNA methylation:
Methyl donors: Folate, vitamin B12, B6, choline, betaine — support SAM synthesis for methylation reactions
Exercise: Aerobic exercise modulates DNA methylation at [BDNF](/proteins/bdnf) and inflammatory gene loci
Mediterranean diet: Associated with slower epigenetic aging
Cognitive engagement: Learning and enrichment drive activity-dependent methylation changes
The study of Dna Methylation has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration/mechanisms) and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Brain Atlas Resources
Allen Human Brain Atlas: [DNA Methylation expression search](https://human.brain-map.org/microarray/search/show?search_term=DNA+Methylation)
Allen Mouse Brain Atlas: [DNA Methylation search](https://mouse.brain-map.org/search/index.html?query=DNA+Methylation)
Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
[Coppieters N, et al., Global changes in DNA methylation and hydroxymethylation in Alzheimer's Disease human brain. Acta Neuropathol. 2014;128:487-498. [PubMed (2014)](https://pubmed.ncbi.nlm.nih.gov/25245166/)
[Unknown, Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057-1068. [PubMed (2010)](https://pubmed.ncbi.nlm.nih.gov/22293439/)
[Globisch D, et al., Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One. 2010;5:e15367. [PubMed (2010)](https://pubmed.ncbi.nlm.nih.gov/22353756/)
[Unknown, Day JJ, Sweatt JD. Epigenetic mechanisms in cognition. Nat Rev Neurosci. 2015;16:661-675. [PubMed (2015)](https://pubmed.ncbi.nlm.nih.gov/26043950/)
Unknown, Day K, Bhatt DK. DNA methylation: the epigenetic mechanism of Alzheimer's Disease. Neurosci Bull. 2024. [PubMed (2024)
[Unknown, Horvath S. DNA methylation age of human tissues and [cell types/cell-types). Genome Biol. 2013;14:R115. . [DOI (2013)](https://doi.org/10.1186/gb-2013-14-10-r115)
[Smart E, et al., Epigenetic regulation in neurodegeneration. J Neurochem. 2018;144:124-138. [PubMed (2018)](https://pubmed.ncbi.nlm.nih.gov/29358856/)
Levine ME, et al, An epigenetic biomarker of aging for lifespan and healthspan (2018)
[Unknown, npj Dementia. DNA methylation age from peripheral blood predicts progression to Alzheimer's Disease. npj Dementia. 2025. . [DOI (2025)](https://doi.org/10.1038/s44400-025-00007-1)
Lord J, Cruchaga C, The epigenetic landscape of Alzheimer's Disease (2014)
Pathway Diagram
Mermaid diagram (expand to render)
Pathway Diagram
The following diagram shows the key molecular relationships involving DNA Methylation discovered through SciDEX knowledge graph analysis: